정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2123 | Recruiting | Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus | COVID-19 Pneumonia | Drug: Baricitinib Drug: Dexamethasone Drug: Remdesivir |
Phase 3 | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | OTHER | 382 | All | 18 Years | Debidwar Upazila Health Complex, Comilla, Bangladesh BIRDEM General Hospital, Dhaka, Bangladesh Mugda Medical College and Hospital, Dhaka, Bangladesh Kurmitola General Hospital, Dhaka, Bangladesh Kurigram Adhunik Sadar Hospital, Kurigram, Bangladesh Rajshahi Medical College & Hospital, Rajshahi, Bangladesh Dedicated Corona Isolation Hospital (DCIH), Rangpur, Bangladesh |
| 2122 | Not yet recruiting | Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. | Pharmacological Action | Drug: Baricitinib | Phase 3 | Hospital of Prato | OTHER | 200 | All | 18 Years ~ 85 Years | Fabrizio Cantini, Prato, Tuscany, Italy |
| 2121 | Completed | Baricitinib Therapy in COVID-19 | Pneumonia | Drug: Baricitinib 4 MG Oral Tablet | Phase 3 | Fabrizio Cantini | OTHER | 12 | All | 18 Years ~ 85 Years | Fabrizio Cantini, Prato, Tuscany, Italy |
| 2120 | Terminated | Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19 | Symptomatic COVID-19 Infection Laboratory-Confirmed | Drug: Baricitinib Drug: Hydroxychloroquine Drug: Placebo Administration |
Phase 2 | University of Southern California, National Cancer Institute (NCI) | OTHER | 6 | All | 18 Years | Los Angeles County-USC Medical Center, Los Angeles, California, United States USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States |
| 2119 | Suspended | BAttLe Against COVID-19 Using MesenchYmal Stromal Cells | Respiratory Distress Syndrome | Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells | Phase 2 | Instituto de Investigacion Sanitaria de la Fundacion Jimenez Diaz, Instituto de Investigacion Sanitaria y Biomedica de Alicante, Hospital General Universitario Gregorio Maranon, Clinica Universidad de Navarra, Universidad de Navarra, University of Salamanca, Hospital General Universitario de Alicante, Hospital Clinico Universitario Virgen de la Arrixaca | OTHER | 100 | All | 18 Years | Fundacion Jimenez Diaz, Madrid, Spain |
| 2118 | Withdrawn | BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST) | Covid19 | Drug: BCG Vaccine Other: Placebo |
Phase 3 | Harvard Medical School (HMS and HSDM), Texas Medical Research Associates, L.L.C. | OTHER | 0 | All | 70 Years | |
| 2117 | Recruiting | BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic | Absenteeism | Biological: BCG-Denmark Biological: Saline |
Phase 4 | University of Southern Denmark, Institute of Hygiene and Tropical Medicine, NOVA University, Lisbon, Portugal, University of Cape Verde, Praia, Cape Verde, National Institute of Public Health of Cape Verde, Praia, Cape Verde, Centro de Investigacao em Saude de Manhica, European and Developing Countries Clinical Trials Partnership (EDCTP), Bandim Health Project, Bissau, Guinea-Bissau | OTHER | 1050 | All | 18 Years | Cape Verde, Praia, Santiago, Cape Verde Bandim Health Project, Bissau, SAB, Guinea-Bissau Manhica Health Research Centre, Manhica, Maputo, Mozambique |